Research programme: MAP4K1 inhibitors - Ichnos Sciences
Latest Information Update: 28 Dec 2023
At a glance
- Originator Ichnos Sciences
- Class
- Mechanism of Action MAP kinase kinase kinase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for research development in Unspecified in USA
- 18 Nov 2019 Research programme: MAP4K1 inhibitors - Ichnos Sciences is available for licensing as of 27 Nov 2019. https://www.ichnossciences.com/partner/
- 18 Nov 2019 Early research in Unspecified in USA (unspecified route)